Form 4: Apogee Therapeutics CFO Granted Stock Options

Apogee Therapeutics' Chief Financial Officer, Jane Pritchett Henderson, has been granted stock options for 124,962 shares.

Summary

• Apogee Therapeutics has granted its Chief Financial Officer, Jane Pritchett Henderson, stock options to purchase 124,962 shares of the company's common stock.
• The options were granted on December 9, 2024, at an exercise price of $49.07 per share.
• The options will vest in 48 equal monthly installments over a four-year period, contingent upon Ms. Henderson's continued employment with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice of incentivizing key personnel with stock options, which is generally viewed positively. There are no indications of any negative issues.

Positives

• The granting of stock options aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Risks

• The value of the options is dependent on the future performance of Apogee Therapeutics' stock price.
• If Ms. Henderson leaves the company before the options fully vest, she may forfeit some or all of the options.

Future Outlook

The stock options will vest over the next four years, incentivizing the CFO to contribute to the company's long-term success.

Industry Context

Stock option grants are a common form of compensation for executives in the biotechnology industry, aligning their interests with the company's performance and shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry to attract and retain key talent.
• Vesting schedules of four years are also common, ensuring long-term commitment from executives.
• The specific number of options and exercise price would be compared to similar grants at peer companies to assess the competitiveness of the compensation package.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign of management's commitment to the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, equity compensation, CFO, Apogee Therapeutics, vesting, common stock